Actively Recruiting
Open-Label Phase 1 Study of TLN-499 Combined With Venetoclax for Adults With Relapsed or Refractory Solid Tumors
Led by Treeline Biosciences, Inc. · Updated on 2026-10-01
120
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, how the body processes, and early anti-tumor effects of the drug TLN-499 combined with venetoclax in adults who have relapsed or refractory solid tumors, including small cell lung cancer, neuroendocrine cancer, malignant pleural mesothelioma, and synovial sarcoma. This is a first-in-human, open-label, phase 1 trial focused on treatment. Participants will receive specified doses of TLN-499 and venetoclax on certain days during the study. The trial includes dose escalation and dose expansion parts, all conducted without placebo comparison. The drugs are given to evaluate how well participants tolerate the combination and to observe any anti-tumor activity. During the trial, participants will be monitored for dose-limiting toxicities during the first 35 days and adverse events for up to about 2 years. Researchers will assess overall response rate, plasma drug levels, duration of response, progression-free survival, and overall survival. Participants will undergo regular tests and evaluations to measure these outcomes and ensure safety throughout the study period.
CONDITIONS
Brief Title
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Research Team
T
Treeline Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here